1. Buprenorphine/naloxone micro-induction in a tertiary care hospital: a retrospective cohort analysis.
- Author
-
Nunn, Robert, Sylvestre, Anne, Sequeira, Kelly, and Tanzini, Rosa Maria
- Subjects
SUBSTANCE abuse ,COMBINATION drug therapy ,PATIENT compliance ,TERTIARY care ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,LONGITUDINAL method ,OPIOID analgesics ,MEDICAL records ,ACQUISITION of data ,NALOXONE ,DRUGS ,BUPRENORPHINE ,PATIENTS' attitudes - Abstract
Objectives: To describe the use of buprenorphine/naloxone micro-inductions in hospitalized patients and characterize the success rate of these inductions. Methods: We conducted a retrospective chart review of hospitalized patients receiving a buprenorphine/naloxone micro-induction for opioid use disorder in a tertiary care hospital from Jan 2020–Dec 2020. The primary outcome was a description of the micro-induction prescribing patterns used. The secondary outcomes were a description of the demographic characteristics of patients, the estimated frequency of withdrawal symptoms experienced by patients undergoing a micro-induction, and the overall success rate of the micro-inductions defined as retention on buprenorphine/naloxone therapy with no precipitated withdrawal experienced. Results: Thirty-three patients were included in the analysis. Three main micro-induction regimens were identified, including rapid micro-inductions (8 patients), 0.5 mg SL BID initiations (6 patients), and 0.5 mg SL daily initiations (19 patients). Twenty-four patients (73%) met the criteria for a successful micro-induction, defined as being retained in buprenorphine/naloxone therapy with no precipitated withdrawal experienced. The most common reason for micro-induction failure was patient request to discontinue buprenorphine/naloxone therapy due to perceived adverse effects or personal preference. Conclusion: Buprenorphine/naloxone micro-induction in hospitalized patients resulted in a majority of patients being successfully initiated on buprenorphine/naloxone therapy without requiring opioid abstinence prior to induction. Dosing regimens were variable, and the ideal regimen remains unclear. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF